NEWS: Infermedica named to the 2022 CB Insights’ Digital Health 150 List
Diamond illustration

undefined NaN, NaN

We’re pleased to announce that CB Insights has named Infermedica to its fourth annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022. Our company was recognized in the Screening, Monitoring and Diagnostics area for its Medical Guidance Platform and we couldn’t be happier to share this amazing news with you!

CB insights and Infermedica logo

Infermedica named to the 2022 CB Insights’ Digital Health 150 List. Image by Tomek Tuz.

Utilizing the CB Insights platform, the research team selected 150 winners from a pool of over 13,000 private companies, including applicants and nominees. The winners were chosen based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty. The research team also reviewed over 3,000 Analyst Briefings submitted by applicants. When taking into account these considerable requirements, this achievement becomes even greater for us!

Get the latest from the Infermedica blog

"From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s Digital Health 150 winners are transforming the future of healthcare with digital technology. This increasingly global cohort, representing more than 18 countries across five continents, is not only driving better patient outcomes, but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year’s winners.”

Brian Lee / SVP, CB Insights’ Intelligence Unit

CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, CB Insights has created a platform where clients can manage their entire end-to-end technology decision-making process. Since 2017, this year's Digital Health 150 winners have raised around $5.6B in equity funding across 378 deals. This includes approximately $1.6B raised across 85 deals in 2022 YTD alone.

Logos of companies recognized in this year’s CB insights Digital Health 150

Companies recognized in this year’s CB insights Digital Health 150.

“Infermedica was founded to transform healthcare outcomes by making primary care accessible to all. Being recognized in the Digital Health 150 exemplifies our unwavering commitment to help millions of people worldwide through their patient journey. Our Medical Guidance Platform has been used by over 12 million people in 30 countries, and by automating the process of symptom assessment, lets us continue to support our patients with their common health complaints. We are privileged to be included alongside other revolutionary healthcare companies."

Piotr Orzechowski / CEO and Co-Founder, Infermedica

It is estimated that up to five billion people will not have access to basic healthcare by 2030. Provider shortages and burnout are the primary causes and both are increasing at alarming rates. That’s why we’re dedicated to addressing the challenges faced by healthcare by providing AI-powered solutions for symptom analysis and patient triage.

Read also:

We’re proud to be recognized for our Medical Guidance Platform. The platform leverages powerful, clinically-validated technology and aims to provide personalized patient care from first symptom to post-visit communication and treatment. On top of helping patients, we're also able to utilize our clinical intelligence and technology to support the entire patient-care journey—from Intake, to Triage, and soon Follow-up—and help the physicians, nurses, technicians, medical assistants, and other frontline health workers facing job dissatisfaction and burnout worldwide. Read our new report If you'd like to know more about patient experience and clinician satisfaction in the digital age.

To find out more about the Medical Guidance Platform, get in touch with our team.

BL/EN/2022/12/07/1